Hemab Therapeutics Holdings, Inc.
COAGUnited States
2 filed reports · 116 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
2 reports · Mar 2026 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 2 | 249 | Mar 2026 to Jun 2026 |
Financial data
116 concepts · 249 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial113 concepts · 238 facts · Mar 2025 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value4 · Mar 2025 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations4 · Mar 2025 to Jun 2026
- Comprehensive income net of tax4 · Mar 2025 to Jun 2026
- Depreciation on property plant and equipment4 · Mar 2025 to Jun 2026
- Earnings per share basic4 · Mar 2025 to Jun 2026
- Earnings per share diluted4 · Mar 2025 to Jun 2026
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest4 · Mar 2025 to Jun 2026
- Income tax expense benefit4 · Mar 2025 to Jun 2026
- Interest income other4 · Mar 2025 to Jun 2026
- Net income loss4 · Mar 2025 to Jun 2026
- Operating expenses (US GAAP)4 · Mar 2025 to Jun 2026
- Operating income loss4 · Mar 2025 to Jun 2026
- Other comprehensive income loss net of tax4 · Mar 2025 to Jun 2026
- Other comprehensive income unrealized holding gain loss on securities arising during period net of tax4 · Mar 2025 to Jun 2026
- Other operating income4 · Mar 2025 to Jun 2026
- Other operating income expense net4 · Mar 2025 to Jun 2026
- Research and development expense4 · Mar 2025 to Jun 2026
- Selling general and administrative expense4 · Mar 2025 to Jun 2026
- Stockholders equity including portion attributable to noncontrolling interest4 · Mar 2025 to Jun 2026
- Weighted average number of diluted shares outstanding4 · Mar 2025 to Jun 2026
- Weighted average number of shares outstanding basic4 · Mar 2025 to Jun 2026
- Noncurrent assets3 · Mar 2025 to Jun 2026
- Accounts payable current2 · Mar 2026 to Jun 2026
- Accretion of discount on available-for-sale debt securities2 · Mar 2025 to Mar 2026
Product2 concepts · 10 facts · Mar 2025 to Jun 2026
- Research and development expense excluding acquired in process cost6 · Mar 2025 to Jun 2026
- Operating Segments4 · Jun 2025 to Jun 2026
KPI1 concepts · 1 facts · Jun 2026
- Clinical Trial Participants1 · Jun 2026
Segments
10 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service3 members · 10 facts
- Hmb0024 · Mar 2025 to Jun 2026
- Sutacimig4 · Mar 2025 to Jun 2026
- HMB-0032 · Jun 2025 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.